Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has three approved products in collaboration, a broad clinical and pre-clinical product pipeline and four proprietary next generation antibody technologies.
